Gefitinib adopts orphan kinases in leukemia

Research output: Contribution to journalArticle

Abstract

Gefitinib, an orally active small-molecule drug that is used for lung cancer therapy based on its EGFR kinase inhibitory properties, is shown to promote differentiation of leukemic cell lines and primary blasts from AML patients in an EGFR-independent fashion.

Original languageEnglish (US)
Pages (from-to)2600-2601
Number of pages2
JournalBlood
Volume106
Issue number8
StatePublished - Oct 2005

Fingerprint

Orphaned Children
Lung Neoplasms
Leukemia
Phosphotransferases
Cells
Cell Line
Molecules
Pharmaceutical Preparations
Therapeutics
gefitinib

ASJC Scopus subject areas

  • Hematology

Cite this

Gefitinib adopts orphan kinases in leukemia. / Pardanani, Animesh D; Tefferi, Ayalew.

In: Blood, Vol. 106, No. 8, 10.2005, p. 2600-2601.

Research output: Contribution to journalArticle

@article{2d16b67ba3014fadb372beb07058f965,
title = "Gefitinib adopts orphan kinases in leukemia",
abstract = "Gefitinib, an orally active small-molecule drug that is used for lung cancer therapy based on its EGFR kinase inhibitory properties, is shown to promote differentiation of leukemic cell lines and primary blasts from AML patients in an EGFR-independent fashion.",
author = "Pardanani, {Animesh D} and Ayalew Tefferi",
year = "2005",
month = "10",
language = "English (US)",
volume = "106",
pages = "2600--2601",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - Gefitinib adopts orphan kinases in leukemia

AU - Pardanani, Animesh D

AU - Tefferi, Ayalew

PY - 2005/10

Y1 - 2005/10

N2 - Gefitinib, an orally active small-molecule drug that is used for lung cancer therapy based on its EGFR kinase inhibitory properties, is shown to promote differentiation of leukemic cell lines and primary blasts from AML patients in an EGFR-independent fashion.

AB - Gefitinib, an orally active small-molecule drug that is used for lung cancer therapy based on its EGFR kinase inhibitory properties, is shown to promote differentiation of leukemic cell lines and primary blasts from AML patients in an EGFR-independent fashion.

UR - http://www.scopus.com/inward/record.url?scp=27144473650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144473650&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:27144473650

VL - 106

SP - 2600

EP - 2601

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -